Alessandro Salvi
Alessandro Salvi
affiliation: Università di Brescia
research area(s): Molecular Biology
Course: Molecular Genetics, Biotechnologies and Experimental Medicine
University/Istitution: Università di Brescia
1998: Degree in Biological Sciences, University of Milan, Italy.
1999-2000: post-Degree training, University of Brescia, Italy.
2000: Qualifying examination (Biologist book subscription N. 058866).
2000-2002: Research and Study Grant, E.U.L.O. (Ente Universitario Lombardia Orientale), UniBS.
2004: Specialization Degree in Medical Genetics, University of Brescia.
2002-2010: Research Fellow at the Division of Biology and Genetics, Dept. of Biomedical Sciences and Biotechnologies, University of Brescia
2010-present: Assistant Professor of Applied Biology, Faculty of Medicine and Surgery, University of Brescia. As a teacher, AS gives the following courses: Applied Biology, general Biology and Biology and Genetics for health profession students (Faculty of Medicine, University of Brescia).
Member of the Board of the PhD program on Molecular Genetics applied to Medical Sciences.
Member of SIC (Società Italiana di Cancerologia)
Member of EACR (European Association for Cancer Research)
Member of AIBG (Associazione Italiana di Biologia e Genetica Generale e Molecolare)
Referee for International journal in the field of RNAi, microRNA, HCC.
Evaluator of Research projects (MIUR).
The main professional skills that have been acquired by AS are comprised in the field of the Molecular Oncology and Genetic Oncology. 2002-2008, development and effectiveness analysis of the plasmid constructs for the stable expression in vitro and in vivo of antisense RNA and shRNA against urokinase (UK) and MET, unfavourable prognostic factors and molecular targets for the human hepatocellular carcinoma (HCC). 2009-2012, miRs biological validation as negative regulators of UK and MET identified by bioinformatic tools to better understand the UK and MET post-transcriptional regulation. Development of small RNA expression library in HCC cell line and expression study of the most abundant. We have identified some miRs differentially expressed in cirrhotic HCCs respect to non-cirrhotic ones. Identification of a novel miRNA by sequence alignement (hsa-miR-1199) and submission of the sequence to the miRBASE official registry.

Current Research interests
- bioinformatic prediction and experimental validation of miRNAs targeting genes involved in the control of cancer cell malignant properties. Study of miRNAs expression to identify novel biomarkers for human hepatocellular carcinoma (HCC) stratification, early diagnosis and follow-up of patients.
-Study of the epigenetic-mediated control of miRNA expression development of innovative therapeutics in HCC: in vitro models of treatments with miR-23b and miR-193a as novel therapeutic tools for HCC.
-Epigenetic and epigenomic alterations in breast cancer and HCC.
Salvi A., Abeni E., Portolani N., Barlati S., De Petro G.
Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC
Int. J. Oncol. 2012, in press DOI: 10.3892/ijo.2012.1716

Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S.
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.
Oncogene. 2012 Jan 16.

Moncini S, Salvi A, Zuccotti P, Viero G, Quattrone A, Barlati S, De Petro G, Venturin M, Riva P.
The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration.
PLoS One. 2011;6(5):e20038

Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, Gervasi M, Caimi L, Barlati S.
BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Oncol Rep. 2010 Dec;24(6):1661-7.

Salvi A., Sabelli C., Moncini S., Venturin M., Arici B., Riva P., Portolani N., Giulini S. M., De Petro G.and Barlati S.
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
FEBS J. 2009 Jun;276(11):2966-82

Salvi A, Bongarzone I, Miccichè F, Arici B, Barlati S, De Petro G.
Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells.
Neoplasia. 2009 Feb;11(2):207-19.

Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C.
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.
Neoplasia. 2009 Jan;11(1):10-21.

Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S.
Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Int J Oncol. 2008 Aug;33(2):271-6.

Salvi A., Arici B., Portolani N., Giulini S.M., De Petro G., Barlati S.
In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells.
Int J Oncol. 2007 Aug;31(2):451-60

Zoppi N., Ritelli M., Salvi A., Colombi M., Barlati S.
The FN13 peptide inhibits human tumor cells invasion through the modultation of v3 integrins organization and the inactivation of ILK pathway.
BBA-Molecular Cell Research, 2007; 1773: 747-763

Salvi A., Arici B., Alghisi A., Barlati S.and De Petro G.
RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice.
Tumour Biol. 2007;28(1):16-26.
Project Title:
Study of the Epigenome of Solid Cancers
Use of Affymetrix human promoter array 1.0R to analyze the DNA methylation profile of solid cancers (breast cancer and HCC) to better understand the molecular mechanism of carcinogenesis and to pursue advances in personalized medicine